A role for PARP inhibitors in HER2-positive breast cancer?

摘要

PARP inhibitors have been shown to have clinical activity in HER2-positive breast cancer, independent of deficiency in homologous recombination. The research, published in the journal Cancer Research, suggests that PARP inhibitors could provide a novel therapeutic strategy in the treatment of sporadic HER2-positive breast cancer.HER2 overexpression in breast cancer is associated with increased tumor aggressiveness. Although anti-HER2 therapies have revolutionized the treatment of women with HER2-positive breast cancer, resistance occurs in many patients. PARP inhibitors target homologous recombination-deficient tumors, and have been shown to have clinical activity in women with familial breast and ovarian cancers linked to BRCA mutations.